Clinical Report: Surgical Results for Thyroid Nodules Classified as Bethesda System Categories I, II, and III
Overview
Revise to specify that the malignancy rate of 32.3% applies to all classes I-III.
Background
Thyroid nodules are common, with a notable percentage harboring malignancy. The Bethesda System for Reporting Thyroid Cytopathology provides a framework for assessing the risk of cancer in these nodules, guiding clinical decision-making. Understanding the malignancy rates associated with different Bethesda categories is crucial for optimizing management strategies and surgical interventions.
Data Highlights
Bethesda Class
Malignancy Rate
I
23.5%
II
20.4%
III
49.4%
Key Findings
Carcinoma was confirmed in 32.3% of patients with Bethesda classes I–III nodules.
Malignancy rates were 23.5% for class I, 20.4% for class II, and 49.4% for class III nodules.
Papillary thyroid carcinoma (PTC) was the most common malignant type, accounting for 54.8% of cases.
Atypia with both nuclear and architectural features (AUS-N/A) was identified as an independent predictor of malignancy in class III nodules.
Increased nodule size on ultrasound was associated with a higher risk of malignancy in class III nodules.
The prognosis after surgery for Bethesda classes I, II, and III was favorable with a low recurrence rate.
Clinical Implications
Discuss the implications of AUS-N/A in decision-making for all Bethesda classes.
Conclusion
Bethesda class III nodules present a heightened risk of malignancy, warranting careful evaluation and potential surgical intervention. The study reinforces the need for a nuanced approach to thyroid nodule management.
